Chronic administration of sildenafil modified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction

Journal of Sexual Medicine

Volumn 7, Issue 12, 2010, Pages 3868-3878

  Liu, Guihua ^a   Sun, Xiangzhou ^a   Dai, Yuping ^a   Zheng, Fufu ^a   Wang, Daohu ^a   Huang, Yanping ^a   Bian, Jun ^a   Deng, Chunhua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chronic Administration; Diabetic Erectile Dysfunction; Endothelial Dysfunction; Nitric Oxide Synthase; Sildenafil; VEGF

Indexed keywords

APOMORPHINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; SILDENAFIL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; WESTERN BLOTTING;

EID: 78649872056     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01844.x     Document Type: Article

References (33)

1. Angulo J, Peiró C, Cuevas P, Gabancho S, Fernández A, González-Corrochano R, La Fuente JM, Baron AD, Chen KS, De Tejada IS. The novel antioxidant, AC3056 (2, 6-di-t-butyl-4-((dimethyl-4-methoxyphenylsilyl)methyloxy)phenol), reverses erectile dysfunction in diabetic rats and improves NO-mediated responses in penile tissue from diabetic men. J Sex Med 2009;6:373-87.
2. Yang R, Yang B, Wen Y, Fang F, Cui S, Lin G, Sun Z, Wang R, Dai Y. Losartan, an Angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats. J Sex Med 2009;6:696-707.
3. Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003;26:1093-9.
4. Goldstraw MA, Kirby MG, Bhardwa J, Kirby RS. Diabetes and the urologist: A growing problem. BJU Int 2007;99:513-7.
5. Angulo J, González-Corrochano R, Cuevas P, Fernández A, Fuente JM, Rolo F, Allona A, Sáenz de Tejada I. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J Sex Med 2010;7:758-68.
6. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6:1232-47.
7. Sáenz de Tejada I, Angulo J, Cellek S, González-Cadavid N, Heaton J, Pickard R, Simonsen U. Pathophysiology of erectile dysfunction. J Sex Med 2005;2:26-39.
8. Jesmin S, Sakuma I, Salah-Eldin A, Nonomura K, Hattori Y, Kitabatake A. Diminished penile expression of vascular endothelial growth factor and its receptors at the insulin-resistant stage of a type II diabetic rat model: A possible cause for erectile dysfunction in diabetes. J Mol Endocrinol 2003;31:401-18.
9. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999;48:1-9.
10. Montorsi F, McDermott TE, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999;53:1011-8.
11. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999;281:421-6.
12. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002;14:466-71.
13. Hidalgo-Tamola J, Chitaley K. Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med 2009;6:916-26.
14. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404.
15. Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW, Kang SK, Lee BC, Hwang WS. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005;28:260-6.
16. Milani E, Nikfar S, Khorasani R, Zamani MJ, Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 2005;140:251-5.
17. De Young L, Yu D, Freeman D, Brock GB. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. Int J Impot Res 2003;15:347-54.
18. Bella AJ, Deyoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 2007;52:990-1005.
19. Vidavalur R, Penumathsa SV, Zhan L, Thirunavukkarasu M, Maulik N. Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor. Vascul Pharmacol 2006;45:91-5.
20. Zhang R, Wang L, Zhang L, Chen J, Zhu Z, Zhang Z, Chopp M. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ Res 2003;92:308-13.
21. Heaton JP, Varrin SJ, Morales A. The characterization of a bio-assay of erectile function in a rat model. J Urol 1991;145:1099-102.
22. Giuliano F, Bernabe J, Jardin A, Rousseau JP. Antierectile role of the sympathetic nervous system in rats. J Urol 1993;150:519-24.
23. De Young LX, Domes T, Lim K, Carson J, Brock GB. Endothelial rehabilitation: The impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 2008;54:213-20.
24. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem 1999;274:33057-63.
25. Lin CS, Ho HC, Chen KC, Lin G, Nunes L, Lue TF. Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. BJU Int 2002;89:955-60.
26. El-Sakka AI. Efficacy of sildenafil citrate in treatment of erectile dysfunction: Effect of type 2 diabetes. Eur Urol 2004;46:503-9.
27. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, Rosano GM. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008;25:37-44.
28. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007;56:1025-33.
29. Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabé J, Burgess G, Wayman C, Alexandre L, Giuliano F. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis. Eur Urol 2005;47:87-91.
30. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol 2009;181:245-51.
31. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: Role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 2005;68:226-32.
32. Thompson CS, Mumtaz FH, Khan MA, Wallis RM, Mikhailidis DP, Morgan RJ, Angelini GD, Jeremy JY. The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. Eur J Pharmacol 2001;425:57-64.
33. Zheng H, Bidasee KR, Mayhan WG, Patel KP. Lack of central nitric oxide triggers erectile dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol 2007;292:R1158-64.